- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03062384
AT-001 for Long-term Preservation of Brain Health in Aging (ALPHA)
AT-001 for Long-term Preservation of Brain Health in Aging: The ALPHA Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Double blind, placebo-controlled, single-center study. Approximately 40 healthy volunteers will be randomized to the study drug and 20 healthy volunteers randomized to the placebo, for a total of 60 enrolled participants.
All participants will be treated with the study drug or placebo for 12 months. Subjects will be seen in the clinic for the following visits: Screening (Day -14), Baseline (Day 0), Month 6, and End-of-Study (Month 12) while on study drug. An additional safety visit at Month 13 (four weeks after study drug discontinuation) will be required of all participants.
Participants will undergo vital signs assessment, medical history review, medication list review, and review of Adverse Events (AEs) and Serious Adverse Events (SAEs) at each visit.
Participants will undergo neuropsychological testing and routine physical examinations at the screening, baseline, and end-of-study visits.
Participants will undergo blood draws, urine collection, MRI to assess lumbar puncture safety, and lumbar puncture at the baseline and end-of-study visits.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Kentucky
-
Lexington, Kentucky, United States, 40504
- University of Kentucky Sanders-Brown Center on Aging Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Not demented by DSM-IV criteria.
- English-speaking, to ensure compliance with cognitive testing and study visit procedures.
- Montreal Cognitive Assessment (MoCA) score at screening visit ≥24/30.
- Female participants must not be pregnant or of childbearing potential (surgically sterile or post-menopausal for >1 year).
- Stable medical condition for 3 months prior to screening visit in the opinion of the study physician.
- Non-diabetic, confirmed by fasting serum glucose <120 mg/dL and on no oral hypoglycemic agents or insulin treatment.
- No other clinically significant abnormalities on labs (CBC, chemistry panel, PT/INR, aPTT, urinalysis).
- Stable medications for 4 weeks prior to screening.
- Able to ingest oral medications.
- Physically acceptable for the study as confirmed by medial history, physical exam, neurological exam, and clinical tests in the opinion of the study physician.
Exclusion Criteria:
- Significant neurological disease, such as Parkinson's disease, brain tumor, multiple sclerosis, or seizure disorder
- Major depression in the past 12 months (DSM-IV criteria), major mental illness such as schizophrenia, or recent (in past 12 months) alcohol or substance abuse.
- History of invasive cancer within the past 2 years (excluding non-melanoma skin cancer).
- Contraindications to lumbar puncture (bleeding disorder, platelet count <100,000, anticoagulant treatment, major structural abnormality or sepsis in the area of the lumbosacral spine, or previous lower back surgery that would make LP technically difficult in the opinion of the study physician, hypersensitivity to lidocaine).
- Contraindications to MRI (pacemaker, shrapnel, metallic implants, etc).
- Clinically significant abnormalities on labs (CBC, chemistry panel, PT/INR, aPTT, urinalysis).
- Use of any investigational agents within 30 days prior to screening.
- Major surgery within eight weeks prior to the Baseline Visit.
- Severe unstable major medical illnesses, including uncontrolled cardiac conditions or heart failure (New York Heart Association Class III or IV).
- Antiretroviral therapy for human immunodeficiency virus (HIV).
- Residence in a skilled nursing facility.
- Blindness, deafness, language difficulties, or any other disability which may prevent the participant.
Excluded Medications:
- Experimental drugs.
- Coumadin, heparin, or any other anticoagulant.
- Insulin or other hypoglycemic agents.
- Supplements containing more than 50 µg selenium/day (US RDA) in the 12 weeks prior to screening.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: AT-001
Yeast-selenium supplement
|
|
Placebo Comparator: Placebo
Yeast supplement devoid of selenium
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Cerebrospinal fluid Aβ42
Time Frame: Baseline to End-of-Study (12 months)
|
Baseline to End-of-Study (12 months)
|
Serum levels of prostaglandins PGF2α and PGE2
Time Frame: Baseline to End-of-Study (12 months)
|
Baseline to End-of-Study (12 months)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Urine levels of prostaglandins PGF2α and PGE2
Time Frame: Baseline to End-of-Study (12 months)
|
Baseline to End-of-Study (12 months)
|
Cerebrospinal fluid levels of phosphorylated and total tau protein
Time Frame: Baseline to End-of-Study (12 months)
|
Baseline to End-of-Study (12 months)
|
Volumetric brain MRI measurements
Time Frame: Baseline to End-of-Study (12 months)
|
Baseline to End-of-Study (12 months)
|
Neurocognitive measure: Free and Cued Selective Reminding Test (FCSRT)
Time Frame: Baseline to End-of-Study (12 months)
|
Baseline to End-of-Study (12 months)
|
Neurocognitive measure: Trail-making test parts A and B
Time Frame: Baseline to End-of-Study (12 months)
|
Baseline to End-of-Study (12 months)
|
Neurocognitive measure: Naming, both single letter fluency and animal naming.
Time Frame: Baseline to End-of-Study (12 months)
|
Baseline to End-of-Study (12 months)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Richard R Murphy, MD, University of Kentucky
- Study Director: Ronan Powers, PhD, Alltech Life Sciences Inc.
- Study Director: Gregory A. Jicha, MD, PhD, University of Kentucky
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Oxidative Stress
-
FertilysRecruiting
-
Idaho State UniversityCompletedOxidative StressUnited States
-
Unidad de Investigacion Medica en Enfermedades...Completed
-
University of Sao PauloFundação de Amparo à Pesquisa do Estado de São Paulo; Coordenação de Aperfeiçoamento...Completed
-
Complife Italia SrlMacrofarm Srl; Icim International SrlCompleted
-
Indonesia UniversityIndonesia-MoHCompleted
-
Assiut UniversityCompleted
-
Universidad Católica San Antonio de MurciaCompleted
-
Oregon State UniversityCompleted
-
Nationwide Children's HospitalWithdrawn
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States